Telaprevir + Maraviroc = Precautionary

Effect on Concentration

Telaprevir
No change
Applies within class?
No
Maraviroc
Increase
Applies within class?
No

Pharmacologic Effects

Telaprevir
Effect
N/A
Applies within class?
No
Maraviroc
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 22-Nov-2022

Summary

Concomitant administration of BOC and TVR resulted in increased MVC AUC and plasma concentrations. Recommended dosage of MVC is 150 mg twice daily in patients receiving TVR.

Sources

Maraviroc vs telaprevir ^

Study Design

In an open-label, fixed-sequence study, 14 healthy subjects received maraviroc (MVC) 150 mg twice daily for 5 days (period 1), followed by coadministration of MVC 150 mg twice daily and telaprevir (TVR) 750 mg 3 times daily for 10 days (period 2). Pharmacokinetic (PK) was analyzed on day 5 of period 1 and day 10 of period 2.

Study Results

When TVR 750 mg 3 times daily was administered concurrently with MVC 150 mg twice daily in 14 healthy subjects, geometric mean ratios (GMRs; MVC+TVR/MVC) [90% CIs] of AUC and Cmax, for MVC were 9.49 [7.94, 11.34] and 7.81 [5.92,10.32], respectively.

Study Conclusions

References

Manoli Vourvahis, Anna Plotka, Constantino Kantaridis, Annie Fang, Jayvant Heera. The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers. Journal Of Acquired Immune Deficiency Syndromes. 1999; 5: 564.